GFAP and glioblastoma: Conversely, treatment of GSCs with iloprost resulted in a significant increase in expression of the GSC marker Sox2, and an associated decrease in expression of the differentiation markers, GFAP and β-tubulin, in multiple GSCs and the U87 glioblastoma cell line (Figure 4B).